Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.78 |
| ▸ | TSHR | P16473 | 8/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | AHR | P35869 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22730 | 0.88 | — | — | |
| SCHEMBL8873179 | 0.88 | TP53 (1.00) | TP53TSHRCYP3A4HSD17B10TDP1 | |
| SCHEMBL29349499 | 0.88 | — | — | |
| SCHEMBL30433206 | 0.85 | TP53 (0.93) | TP53TSHRCYP3A4HSD17B10TDP1 | |
| SCHEMBL7641130 | 0.85 | TP53 (0.93) | TP53TSHRCYP3A4HSD17B10TDP1 | |
| SCHEMBL11661765 | 0.85 | TP53 (0.93) | TP53TSHRCYP3A4HSD17B10TDP1 | |
| SCHEMBL5318805 | 0.85 | TP53 (0.93) | TP53TSHRCYP3A4HSD17B10TDP1 | |
| Potassium SCHEMBL29653750 | 0.85 | TP53 (0.93) | TP53TSHRCYP3A4HSD17B10TDP1 | |
| Water SCHEMBL27492714 | 0.85 | TP53 (0.93) | TP53TSHRCYP3A4HSD17B10TDP1 | |
| SCHEMBL11661762 | 0.85 | TP53 (0.93) | TP53TSHRCYP3A4HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966448-B1 | PYRAZINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2003-10-01 | — | — | EP | disclosed |
| US-6599905-B2 | Phenyl or naphthyl-pyrazine compounds useful in the treatment of central nervous system diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-29 | — | — | US | disclosed |
| US-20020169172-A1 | Pyrazine compounds | GLAXO WELLCOME INC. | 2002-11-14 | — | — | US | disclosed |
| US-6479498-B1 | COMPRISE 2-10 SODIUM CHANNEL LIGANDS COVALENTLY CONNECTED BY A LINKER OR LINKERS | THERAVANCE, INC. | 2002-11-12 | — | — | US | disclosed |
| US-6420354-B1 | Sodium channel drugs and uses | ADVANCED MEDICINE, INC. | 2002-07-16 | — | — | US | disclosed |
| WO-1999063984-A9 | NOVEL SODIUM CHANNEL DRUGS AND USES | — | 2002-04-25 | — | — | WO | disclosed |
| US-6255307-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS | GLAXO WELLCOME, INC. | 2001-07-03 | — | — | US | disclosed |
| EP-1085890-A1 | NOVEL SODIUM CHANNEL DRUGS AND USES | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-0966448-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999063984-A1 | NOVEL SODIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1998038174-A1 | PYRAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169172-A1 | Pyrazine compounds | HCRTR1, HCRTR2, GRIN2C | TP53 4223/4885TSHR 600/4885CYP3A4 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.